Business Context and Reporting Period
Company: Drugs Made In America Acquisition Corp. (DMAA)
Filing Type: Form 8-K (Current Report)
Date of Report: April 29, 2026
Event: Entry into a Definitive Merger Agreement with Power Analytics Global Corp. (PAGC), a Delaware corporation focused on artificial intelligence, advanced analytics, and quantum-resistant security solutions. The transaction involves PAGC merging with and into DMAA (or a subsidiary), with the surviving entity intended to trade on The Nasdaq Stock Market LLC.
Key Financial Metrics and Transaction Terms
- Target Enterprise Valuation: $1.0 billion for PAGC, subject to a Valuation Milestone Schedule based on verified revenue contracts delivered at or prior to closing.
- Floor Valuation: $300 million. If the valuation falls below this threshold, parties may renegotiate or terminate the agreement.
- Post-Closing Ownership (Pre-Dilution): Approximately 90% held by former PAGC shareholders and 10% held by existing DMAA shareholders.
- Minimum Cash at Closing: Target of $30 million, with flexibility to close at levels not less than $15 million, subject to valuation and ownership adjustments.
- Debt Condition: PAGC must satisfy a debt-free condition to close.
- Financial Reporting: The filing does not provide specific revenue, profit, cash flow, or margin figures for either entity.
Material Changes and Conditions
The primary material change is the execution of the Merger Agreement on April 29, 2026, and subsequent Amendments No. 1 and No. 2 on April 30, 2026, which corrected inconsistencies regarding governing law (Delaware), termination provisions, and notice addresses.
Conditions to Closing include:
- Approval by DMAA shareholders.
- Effectiveness of the SEC Registration Statement (Form S-4).
- Listing approval for the surviving entity's common stock on a national securities exchange.
- Absence of governmental orders prohibiting the merger.
- PAGC's closing valuation being at or above the $300 million Floor Valuation.
- PAGC's delivery of an intellectual property schedule and evidence of an active GSA CAGE Code.
Outlook, Risks, and Management Commentary
Outlook: Management expects the surviving entity to operate as a publicly traded company on Nasdaq. Governance will be led by individuals designated by PAGC. The transaction is subject to a 12-month deadline from the agreement date, extendable by mutual agreement for up to two additional three-month periods.
Risks and Contingencies:
- Termination Risks: The agreement may be terminated if closing does not occur within the specified timeframe, if shareholder approval is not obtained, if closing cash is insufficient, or if required financing cannot be secured.
- Valuation Risk: Failure to deliver verified revenue contracts at levels required by the Valuation Milestone Schedule could impact the final valuation.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the ability to consummate the transaction, anticipated ownership, and financial results, which are subject to significant risks and uncertainties.
Investor Verification Checklist
- Verify the final exchange ratio and ownership percentages in the upcoming Form S-4 Registration Statement.
- Confirm the amount of cash available in the Trust Account net of redemptions and the status of any PIPE financing.
- Review the Valuation Milestone Schedule to understand how verified revenue contracts impact the $1.0 billion target valuation.
- Monitor the status of PAGC's GSA CAGE Code and intellectual property schedule delivery.
- Assess the risk of shareholder redemptions reducing the closing cash below the $15 million minimum threshold.